Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions | MicrobiomeTrials← Back to trialsNCT07807488
Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2022-03-16Est. Completion: 2022-04-15
Enrollment target: 64 participants Locations- The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Other microbiome trials you might be interested in
DermatomyositisPolymyositisInclusion Body Myositis
This study will evaluate subjects with adult- and childhood-onset myositis to learn more about their cause and the immun…
Atlanta, United States
Parkinson Disease (PD)
The goal of this pilot clinical trial is to learn whether a week-long study combining controlled breathing procedures, i…
Multiple LocationsEst. completion Nov 2026
Respiratory Tract InfectionSmell DisorderInfluenzaRhinosinusitisCOVID-19DepressionParosmiaHyposomiaNormosomiaAnosmia
Background:
Loss of the sense of smell can seriously affect a person's quality of life. The ability to smell can be dam…
Bethesda, United StatesCompleted Sep 30, 2029